Drug Database
AN

antithrombin III (Atenotiv / ATenativ / ATnativ)

✓ Approved

Pfizer, Inc. · SERPINC1 · Cell-based Therapies

What is antithrombin III?

antithrombin III is a cell-based therapies developed by Pfizer, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAtenotiv, ATenativ, ATnativ
CompanyPfizer, Inc.
Drug ClassCell-based Therapies
Molecular TargetSERPINC1
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Pfizer, Inc.

Mechanism of Action

Molecular Targets

antithrombin III acts on 1 molecular target:

SERPINC1serpin family C member 1 (ATIII, AT3D)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

antithrombin III is developed for 3 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved
Vascular disordersThrombosis✓ Approved
Surgical and medical proceduresAdjuvant therapy✓ Approved

Related Research Articles

PubMedSkeletal radiology2026-09-05

Distribution of anterior inferior iliac spine morphology in patients with femoroacetabular impingement syndrome, developmental dysplasia of the hip, and asymptomatic controls: a retrospective cohort study.

Duan Yu-Peng YP, Liu Rong-Ge RG, Han Tian-Yi TY, Huang Hong-Jie HJ et al.

To compare the distribution of anterior inferior iliac spine (AIIS) morphology on three-dimensional computed tomography (3D-CT) among hips with femoroacetabular impingement syndrome (FAIS), developmental dysplasia of the hip (DDH), and an asymptomatic control cohort. In this single-center retrospective cross-sectional study, AIIS morphology was classified on 3D-CT using a four-subtype system. Asymptomatic control hips were selected from individuals undergoing abdominopelvic CT for non-orthopaedic indications, whereas FAIS and DDH hips were identified from patients evaluated for hip-preservation surgery. Lateral center-edge angle (LCEA) was measured on clinical anteroposterior pelvic radiographs or CT-derived anteroposterior digitally reconstructed radiographs, as applicable. AIIS morphology distributions were compared among groups using chi-square testing with post hoc pairwise analyses. Multivariable logistic regression was used to identify independent predictors of Type III morphology after adjustment for diagnostic group, LCEA, age, and sex. A total of 1,420 hips were analyzed, including 800 asymptomatic hips, 500 FAIS hips, and 120 DDH hips. AIIS morphology distribution did not differ significantly between the FAIS and asymptomatic cohorts. Type III morphology was identified in 9.2% and 9.3% of hips in these two groups, respectively. In contrast, the DDH cohort showed a significantly different distribution, with Type III morphology present in 60.0% of hips. On multivariable analysis, DDH remained the strongest independent predictor of Type III morphology (adjusted odds ratio, 7.99; 95% confidence interval, 3.33-19.14; P < 0.001). Static 3D-CT AIIS morphology did not distinguish FAIS hips from asymptomatic hips. In contrast, Type III morphology was markedly more common in DDH, suggesting that AIIS morphology should be interpreted in the context of acetabular coverage and the underlying hip disorder.

PMID 42698014
Read full article →
PubMedUrologie (Heidelberg, Germany)2026-09-05

[Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].

Gakis Georgios G, Vom Dorp Frank F

Intravesical Bacillus Calmette-Guerin (BCG) therapy following transurethral resection (TURBT) remains an important standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC). Recent phase III trials have evaluated the addition of immune checkpoint inhibitors (IO) to further reduce recurrence rates. This review synthesizes data from the CREST (sasanlimab), POTOMAC (durvalumab), and ALBAN (atezolizumab) trials, focusing on surgical quality, BCG maintenance duration, and primary endpoint definitions. CREST and POTOMAC demonstrated significant improvements in event-free or disease-free survival (both hazard ratio [HR] 0.68) when a 2-year BCG maintenance schedule was followed. In contrast, the ALBAN trial (HR 0.98) failed its primary endpoint. Key reasons for this discrepancy include the shortened BCG maintenance (1 year) and the inclusion of low-grade recurrences in the primary endpoint, which by international consensus do not constitute BCG failure. Data also show that IO cannot compensate for the omission of BCG maintenance. Severe systemic toxicity (grade 3-5) increased substantially with the combination therapy (up to 29%). Combination therapy strictly necessitates the full BCG maintenance schedule. Given the significant systemic toxicity and the current lack of a demonstrated overall survival benefit, careful patient selection is mandatory.

PMID 42697960
Read full article →
PubMedBritish journal of cancer2026-09-05

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

Hirano Hidekazu H, Yamada Yasuhide Y, Nagashima Kengo K, Hiraoka Nobuyoshi N et al.

The prognostic significance of PD-L1 expression in unresectable/recurrent gastric cancer treated by first-line chemotherapy without an immune checkpoint inhibitor (ICI) remains unclear. The phase III trial JCOG1013 demonstrated no overall survival (OS) or progression-free survival (PFS) benefit of docetaxel/cisplatin/S-1 over cisplatin/S-1. This ancillary analysis of JCOG 1013 evaluated the prognostic value of PD-L1 expression. PD-L1 expression was assessed in pretreatment tumor specimens using the Dako 28-8 pharmDx assay. Combined positive score (CPS) and tumor proportion score (TPS) were calculated. PD-L1 positivity was defined as CPS ≥ 5 or TPS ≥ 1%. Univariable and multivariable analyses were performed for OS and PFS. Among 741 patients enrolled in JCOG1013, 540 patients were included. In univariable analyses, neither CPS ≥ 5 nor TPS ≥ 1% was significantly associated with OS or PFS. In multivariable analyses, CPS ≥ 5 was not significantly associated with OS (HR 0.86, 95% CI 0.71-1.04; p = 0.127) or PFS (HR 0.92, 95% CI 0.77-1.11; p = 0.392); however, TPS ≥ 1% was significantly associated with longer OS (HR 0.78, 95% CI 0.62-0.97; p = 0.028) and PFS (HR 0.76, 95% CI 0.62-0.94; p = 0.012). TPS ≥ 1% is an independent favorable prognostic factor for survival in patients with unresectable/recurrent gastric cancer receiving chemotherapy alone. UMIN000007652.

PMID 42697937
Read full article →
PubMedCanadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes2026-09-05

CT-Guided Inferior Rectal Nerve Block for Postoperative Pain Management After Hemorrhoidectomy.

Chang Ching-Di CD, Lee Sieh-Yang SY, Chen Chi-Cheng CC, Chen Yun-Ting YT et al.

Hemorrhoidectomy is among the most painful procedures in colorectal surgery. Effective postoperative pain management remains an unmet clinical need. To evaluate the efficacy, duration of analgesia, and safety of CT-guided inferior rectal nerve block (IRNB) for postoperative pain management following hemorrhoidectomy. This retrospective study enrolled 69 patients with grade III or IV mixed hemorrhoids undergoing hemorrhoidectomy between April 2024 and March 2026. Patients who elected to receive IRNB were assigned to Group 1 (n = 38); those who declined formed Group 2 (n = 31, standard analgesia). Group 1 received bilateral CT-guided IRNB on postoperative day 1 using a mixture of triamcinolone acetonide, 0.5% bupivacaine HCl, normal saline, and epinephrine. Pain intensity was assessed using the Numerical Rating Scale (NRS, 0-10) at baseline and on postoperative days 1 to 10, 14, and 28. Analgesic use and complications were also recorded. Group 1 showed significantly lower median NRS scores than Group 2 on postoperative day 1 (2 [1-5] vs 5 [4-7]; P < .001), with sustained superiority through day 14 (1 [0-1] vs 2 [0-3]; P < .05). A secondary pain peak occurred in Group 1 on day 4 (4 [2-5]), consider pharmacological attrition and pain rebound. Both groups reached near-complete pain resolution by day 28. Complication rates did not differ significantly between groups. CT-guided IRNB may provides effective and safe postoperative analgesia following hemorrhoidectomy, with significant pain control over the first 2 postoperative weeks.

PMID 42698285
Read full article →
PubMedThe American journal of occupational therapy : official publication of the American Occupational Therapy Association2026-09-05

Extrinsic Environmental Factors Influencing the Achievement of Independent Oral Feeding in Preterm Infants.

Cushing Avery A, Donovan Karlee K, Lewis Jasmine J, Lucyshyn Katja K et al.

ImportancePreterm infants frequently experience difficulty with the transition from full tube to independent oral feeding. The influence of extrinsic environmental factors, defined as causes external to the infant, that may affect this transition remains poorly understood.ObjectiveTo examine the association between extrinsic environmental factors and attainment of independent oral feeding in preterm infants.DesignA retrospective cohort study was conducted.SettingData were collected from a tertiary care, level II/III neonatal intensive care unit. Guided by the Oral Feeding in Preterm Infants Conceptual Model, extrinsic environmental factors were selected for analysis.ParticipantsA total of 282 preterm infants (31.2 ± 2.4 weeks gestation) were included.MethodologyFactors including maternal medical history, type of medical condition, maternal substance use, non-nutritive sucking, skin-to-skin contact, feeding therapy, and days of hospitalization prior to initiating oral feeding were extracted from electronic medical records. Simple linear regressions identified potential external variables, which were entered into a multiple linear regression model.ResultsIn the final multiple linear regression model, maternal medical history, non-nutritive sucking, and skin-to-skin contact were significant predictors of time to independent oral feeding. Maternal age, substance use, feeding therapy, and days in hospital prior to starting oral feeds were not significant.Conclusion and RelevanceMaternal health and engagement, reflected in maternal medical history, opportunities for non-nutritive sucking, and skin-to-skin contact, are key extrinsic environmental factors influencing the transition to independent oral feeding. Integrating these maternal factors into occupational therapy management may enhance the attainment of independent oral feeding in preterm infants.

PMID 42698322
Read full article →
PubMedBMC oral health2026-09-05

Evaluation of postoperative pain associated with different working length determination methods: a randomised clinical study.

Nalci Calik Gamze G, Alim Uysal Betül Aycan BA, Peker Fatma Begüm FB, Guneser Mehmet Burak MB

Postoperative pain is a common concern in endodontic treatment. In teeth with asymptomatic irreversible pulpitis, accurate working length determination is critical for effective root canal therapy and may influence postoperative discomfort. This study compared postoperative pain following root canal treatment in teeth with asymptomatic irreversible pulpitis when working length was determined using one of four electronic apex locators or periapical radiography. A total of 125 patients with asymptomatic irreversible pulpitis in single-rooted, single-canal teeth were included in the analysis. Patients were randomly assigned to five groups according to the working length determination method: Root ZX, Propex Pixi, Woodpex III, Raypex 6, or periapical radiography. A single clinician performed standardised root canal treatment in a single visit. Pain was assessed using the visual analogue scale at 6, 12, 24, and 48 hours postoperatively, and analgesic intake was recorded. Postoperative pain gradually decreased over time in all groups. No statistically significant differences in postoperative pain were observed among the five working length determination methods at any postoperative assessment time point (all P > 0.05). Furthermore, postoperative pain was not significantly associated with age, sex, tooth location, and analgesic intake did not differ significantly among the groups. Under the standardised clinical conditions of this randomised clinical trial, the method used for working length determination did not significantly influence postoperative pain after single-visit root canal treatment in patients with asymptomatic irreversible pulpitis. This study was retrospectively registered at ClinicalTrials.gov (Identifier: NCT07271797) on November 16, 2025. However, the study protocol, eligibility criteria, primary and secondary outcome measures, and statistical analysis plan were established before patient enrolment.

PMID 42698074
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about antithrombin III